Randomized trial of high-dose chemotherapy and autologous hematopoietic stem cell support for high-risk primary breast carcinoma: follow-up at 12 years

Cancer
Emer O HanrahanGabriel N Hortobagyi

Abstract

The authors previously reported results from a randomized trial of standard-dose chemotherapy with combined 5-fluorouracil (1000 mg/m2 per cycle), doxorubicin (50 mg/m2 per cycle), and cyclophosphamide (500 mg/m2 per cycle) (FAC) versus FAC followed by high-dose chemotherapy (HDCT) and autologous stem cell support (ASCS) for patients with high-risk primary breast carcinoma. After a median follow-up of 6.5 years, no significant differences were observed in recurrence-free survival (RFS) or overall survival (OS) between the 2 arms. This report updates the survival analyses. Patients with >or=10 positive axillary lymph nodes after primary surgery or >or=4 positive lymph nodes at surgery after neoadjuvant chemotherapy were eligible. All patients were to receive 8 cycles of FAC. Patients were assigned randomly to receive either no further chemotherapy or 2 cycles of combined high-dose cyclophosphamide (5250 mg/m2 per cycle), etoposide (1200 mg/m2 per cycle), and cisplatin (165 mg/m2 per cycle) with ASCS. Primary endpoints were RFS and OS. RFS and OS were calculated by using the Kaplan-Meier method. The log-rank statistic was used to compare treatment arms. Between 1990 and 1997, 78 patients were registered, and 39 patients were assi...Continue Reading

References

Apr 1, 1989·American Journal of Clinical Oncology·A U BuzdarG N Hortobagyi
Sep 1, 1988·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·I C HendersonR Gelman
Aug 1, 1986·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·W Hryniuk, M N Levine
Nov 1, 1984·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·W Hryniuk, H Bush
May 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·K H AntmanM M Horowitz
Aug 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G SomloA Molina
Feb 3, 2000·Journal of the National Cancer Institute·G N HortobagyiR E Champlin
Feb 25, 2003·Cancer Control : Journal of the Moffitt Cancer Center·Henri RocheUNKNOWN PEGASE Group
Mar 15, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·I Craig HendersonLarry Norton
Jul 4, 2003·The New England Journal of Medicine·Sjoerd RodenhuisUNKNOWN Netherlands Working Party on Autologous Transplantation in Solid Tumors
Mar 12, 2004·The New England Journal of Medicine·R Charles CoombesUNKNOWN Intergroup Exemestane Study
Jul 22, 2004·Journal of the National Cancer Institute·Robert C F LeonardUNKNOWN Anglo-Celtic Cooperative Oncology Group
Jun 3, 2005·The New England Journal of Medicine·Miguel MartinUNKNOWN Breast Cancer International Research Group 001 Investigators
Oct 21, 2005·The New England Journal of Medicine·Martine J Piccart-GebhartUNKNOWN Herceptin Adjuvant (HERA) Trial Study Team
Oct 21, 2005·The New England Journal of Medicine·Edward H RomondNorman Wolmark

❮ Previous
Next ❯

Citations

Aug 1, 2009·Nature Reviews. Clinical Oncology·Fleur HuangWilliam D Foulkes
Jun 18, 2009·Current Opinion in Oncology·Yago Nieto, Elizabeth J Shpall
Nov 17, 2009·The Breast : Official Journal of the European Society of Mastology·Daniel F Hayes
Jan 17, 2009·International Journal of Radiation Oncology, Biology, Physics·Volker W Stieber
Oct 27, 2007·Seminars in Hematology·Paolo PedrazzoliUNKNOWN Gruppo Italiano per il Trapianto di Midollo Osseo, Cellule Staminali Emopoietiche e Terapia Cellulare
Feb 7, 2012·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·A VanderWaldeG Somlo
Jul 11, 2009·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Claude SportèsRonald E Gress
Jul 20, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Donald A BerryTaner Demirer
Feb 16, 2007·Annals of Oncology : Official Journal of the European Society for Medical Oncology·N WilkingJ Bergh

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Related Papers

© 2022 Meta ULC. All rights reserved